Clinical Trial Search

Primary: Percentage Change in CY-BOCS Score From Baseline to Week 9 — 12.1; 31.1 Percentage Change at Week 9 to Baseline — p=0.0718

Primary: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) — 29.49; 28.43; 20.53; 23.45 units on a scale

Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001

Primary: Children's Yale-Brown Obsessive Compulsive Scale Total Score — 20.59; 25.67 units on a scale — p=0.44

Primary: Consumer Assessment of Healthcare Providers and Systems Child Hospital Survey Communication Subscale — 0.769; 0.775; 0.735; 0.747 score on a scale

Primary: Number of Participants Experienced a Relapse of Nephrotic Syndrome — 14; 15 Participants

Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) — 35.3; 13.8 Percentage of study group

Primary: Adverse Events — 4; 4; 2; 17 Adverse events

Primary: Summary of Change From Baseline in Total Sum of McGill Pain Questionnaire to Visit 3 — -14.48 Scores on scale

Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L

Primary: Total Number of Central Line Associated Blood Stream Infections (CLABSI) — 113; 84; 123; 109 infections

Primary: Part A: Maximum Observed Serum Concentration (Cmax) of Evinacumab — 238 Milligrams per Liter (mg/L)

Primary: Time to Failure — 16; 13 Days

Primary: Change From Baseline in Tissue Glycogen Content in Quadriceps Muscle Biopsy Samples at Week 26 — 5.3; -1.6 percent area occupied by glycogen — p=0.1860

Primary: Duration of Continuing Analgesia — 28.6; 2.2; 25.8 hours — p=0.006